Ayala Pharmaceuticals (ADXS) Competitors $0.12 0.00 (0.00%) As of 06/20/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock ADXS vs. QTTB, BIVI, GOVX, IMNN, CGTX, OVID, DRRX, LGVN, CING, and SNYRShould you be buying Ayala Pharmaceuticals stock or one of its competitors? The main competitors of Ayala Pharmaceuticals include Q32 Bio (QTTB), BioVie (BIVI), GeoVax Labs (GOVX), Imunon (IMNN), Cognition Therapeutics (CGTX), Ovid Therapeutics (OVID), DURECT (DRRX), Longeveron (LGVN), Cingulate (CING), and Synergy CHC Corp. (Uplisting) (SNYR). These companies are all part of the "pharmaceutical products" industry. Ayala Pharmaceuticals vs. Its Competitors Q32 Bio BioVie GeoVax Labs Imunon Cognition Therapeutics Ovid Therapeutics DURECT Longeveron Cingulate Synergy CHC Corp. (Uplisting) Ayala Pharmaceuticals (NASDAQ:ADXS) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, community ranking, risk and analyst recommendations. Does the MarketBeat Community believe in ADXS or QTTB? Q32 Bio received 12 more outperform votes than Ayala Pharmaceuticals when rated by MarketBeat users. Likewise, 63.16% of users gave Q32 Bio an outperform vote while only 0.00% of users gave Ayala Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAyala PharmaceuticalsOutperform VotesNo VotesUnderperform Votes87100.00% Q32 BioOutperform Votes1263.16% Underperform Votes736.84% Do analysts rate ADXS or QTTB? Q32 Bio has a consensus target price of $12.17, suggesting a potential upside of 684.95%. Given Q32 Bio's stronger consensus rating and higher probable upside, analysts plainly believe Q32 Bio is more favorable than Ayala Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Q32 Bio 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Do insiders & institutionals have more ownership in ADXS or QTTB? 7.2% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 31.3% of Q32 Bio shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by insiders. Comparatively, 40.0% of Q32 Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media favor ADXS or QTTB? In the previous week, Q32 Bio had 1 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 1 mentions for Q32 Bio and 0 mentions for Ayala Pharmaceuticals. Q32 Bio's average media sentiment score of 1.00 beat Ayala Pharmaceuticals' score of 0.00 indicating that Q32 Bio is being referred to more favorably in the news media. Company Overall Sentiment Ayala Pharmaceuticals Neutral Q32 Bio Positive Which has higher earnings and valuation, ADXS or QTTB? Q32 Bio has lower revenue, but higher earnings than Ayala Pharmaceuticals. Q32 Bio is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAyala Pharmaceuticals$3.24M1.58-$48.07M-$7.98-0.02Q32 Bio$1.16M16.30-$47.73M-$4.94-0.31 Which has more risk & volatility, ADXS or QTTB? Ayala Pharmaceuticals has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Comparatively, Q32 Bio has a beta of -0.03, suggesting that its stock price is 103% less volatile than the S&P 500. Is ADXS or QTTB more profitable? Ayala Pharmaceuticals' return on equity of 0.00% beat Q32 Bio's return on equity.Company Net Margins Return on Equity Return on Assets Ayala PharmaceuticalsN/A N/A N/A Q32 Bio N/A -447.33%-59.77% SummaryQ32 Bio beats Ayala Pharmaceuticals on 12 of the 17 factors compared between the two stocks. Get Ayala Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXS vs. The Competition Export to ExcelMetricAyala PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.13M$762.52M$5.20B$8.59BDividend YieldN/A4.84%5.36%4.20%P/E Ratio-0.021.1425.7519.16Price / Sales1.58223.32395.33100.88Price / CashN/A23.4435.5255.99Price / Book-0.066.277.985.79Net Income-$48.07M-$26.43M$3.15B$248.88M7 Day PerformanceN/A-0.10%1.27%2.13%1 Month PerformanceN/A9.62%4.91%4.30%1 Year Performance-54.17%5.22%41.84%15.71% Ayala Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXSAyala PharmaceuticalsN/A$0.12flatN/A-54.2%$5.13M$3.24M-0.0220Gap UpQTTBQ32 Bio2.9023 of 5 stars$1.68+0.6%$12.17+624.2%-90.3%$20.49M-$6.65M-0.1239Positive NewsShort Interest ↓BIVIBioVie2.2222 of 5 stars$1.09-4.4%$3.00+175.2%+122.0%$20.24MN/A-0.1110Positive NewsGOVXGeoVax Labs3.0931 of 5 stars$1.32+28.2%$11.10+740.9%-50.1%$20.06M$5.59M-0.3610Analyst UpgradeGap UpHigh Trading VolumeIMNNImunon1.9213 of 5 stars$1.14-20.3%$15.50+1,259.6%-3.8%$20.00M$500K-0.6030CGTXCognition Therapeutics3.0607 of 5 stars$0.32+7.9%$5.63+1,646.9%-87.5%$19.96MN/A-0.3320News CoveragePositive NewsOVIDOvid Therapeutics4.5157 of 5 stars$0.29+3.7%$2.78+857.8%-55.7%$19.93M$548K-0.6260News CoveragePositive NewsHigh Trading VolumeDRRXDURECT0.6013 of 5 stars$0.63+2.7%N/A-53.6%$19.61M$1.86M-1.0480Gap DownLGVNLongeveron3.1481 of 5 stars$1.29-0.8%$8.67+571.8%-51.0%$19.26M$2.23M-0.2120Gap UpCINGCingulate2.1678 of 5 stars$4.51+7.4%$26.00+476.5%+567.7%$19.15MN/A-0.5320SNYRSynergy CHC Corp. (Uplisting)3.7432 of 5 stars$2.29+10.1%$10.00+336.7%N/A$19.12M$33.59M0.0040Analyst Upgrade Related Companies and Tools Related Companies Q32 Bio Alternatives BioVie Alternatives GeoVax Labs Alternatives Imunon Alternatives Cognition Therapeutics Alternatives Ovid Therapeutics Alternatives DURECT Alternatives Longeveron Alternatives Cingulate Alternatives Synergy CHC Corp. (Uplisting) Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADXS) was last updated on 6/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredThe IRS Loophole That Lets You Own Gold Tax-FreeWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ayala Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
